High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates

Benzer Materyaller

• Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
  Yazar:: Kaufman, Howard L, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)
  Yazar:: Kaufman, Howard L., ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes
  Yazar:: Wong, Michael K, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
  Yazar:: Clark, Joseph I, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM(SM) registry
  Yazar:: Curti, Brendan, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)